Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning

Pediatric Blood and Cancer

Volumn 46, Issue 4, 2006, Pages 496-500

  Torjemane, L ^a   Ladeb, S ^a   Ben Othman, T ^a   Abdelkefi, A ^a   Lakhal, A ^a   Ben Abdeladhim, A ^a  

^a CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

Author keywords

Allogeneic marrow transplantation; Busulfan conditioning; Cyclophosphamide; Fanconi anemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONDITIONING; DRUG EFFECT; FANCONI ANEMIA; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVING DONOR; LOW DRUG DOSE; MALE; ORGAN DONOR; PRIORITY JOURNAL; PROPHYLAXIS; RARE DISEASE;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FANCONI ANEMIA; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SIBLINGS; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33644671237     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20286     Document Type: Article

References (30)

1. Auerbach AD, Allen RG. Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the international Fanconi anemia registry. Cancer Genet Cytogenet 1991;51:1-12.
2. Alter B. Fanconi's anemia and its variability. Br J Haematol 1993;85:9-14.
3. Butturini A, Gale RP, Verlander PC, et al. Hematological abnormalities in Fanconi anemia: An International Fanconi Anemia Registry study. Blood 1994;84:1650-1655.
4. Bouchlaka C, Abdelhak S, Amouri A, et al. Fanconi anemia in Tunisia: High prevalence of Group A and identification of new FANCA mutations. J Hum Genet; 2003;48:332-361.
5. Gluckman E, Devergie A, Schaison G, et al. Bone marrow transplantation in Fanconi anaemia. Br J Haematol 1980;45:557-567.
6. Gluckman E, Devergie A, Dutreix J. Bone marrow transplantation in Fanconi anaemia. A modified conditioning regimen. Exp Hematol 1982;10:26-27.
7. Socié G, Gluckman E, Raynal B, et al. Bone marrow transplantation for Fanconi anemia using low-dose cyclophosphamide/thoracoabdominal irradiation as conditioning regimen: Chimerism study by the polymerase chain reaction. Blood 1993;82:2249-2256.
8. Gluckman E. Allogeneic bone marrow transplantation in Fanconi anemia. Bone Marrow Transplant 1996;18(Suppl. 3):33-35.
9. Gluckman E, Auerbach AD, Horowitz M, et al. Bone marrow transplantation for Fanconi anemia. Blood 1995;86:2856-2862.
10. Kohli-Kumar M, Morris C, Delaat C, et al. Bone marrow transplantation in Fanconi anemia using matched sibling donors. Blood 1994;84:2050-2054.
11. Deeg HJ, Socié G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients. Blood 1996;87:386-392.
12. Flowers ME, Doney KC, Storb R, et al. Marrow transplantation for Fanconi anemia with or without leukemia transformation: Update of Seattle experience. Bone Marrow Transplant 1992;9:167-173.
13. Flowers M, Zanis J, Pasquini R, et al. Marrow transplantation for Fanconi anaemia: Conditioning with reduced doses of cyclophosphamide without radiation. Br J Haematol 1996;92:699-706.
14. Zanis-Neto J, Pereira NF, de Medeiros CR, et al. Bone marrow transplantation for Fanconi anemia, decreasing the cyclophosphamide dose without irradiation. Blood 1998;92(Suppl. 1):136a (Abstr. 546)
15. Meideros CR, Zanis-Neto J, Pasquini R. Bone marrow transplantation for patients with Fanconi anemia: Reduced doses of cyclophosphamide without irradiation as conditioning. Bone Marrow Transplant 1999;24:849-852.
16. Guardiola Ph, Pasquini R, Dokal I, et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: A study on behalf of the European Group for Blood and Marrow Transplantation. Blood 2000;95:422-429.
17. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow recipients: Long-term follow-up of randomised, placebo-controlled trial. Blood 2000;96:2055-2061.
18. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factor and treatment results. Blood 1989;73:606-613.
19. Leclair B, Frégeau CJ, Aye MT, et al. DNA typing for bone marrow engraftment follow-up after allogeneic transplant: A comparative study of current technologies. Bone Marrow Transplant 1995;16:43-55.
20. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974;18:295-304.
21. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation. New Engl J Med 1975;1:832-843.
22. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosupression. Blood 1975;57:267-276.
23. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
24. Abdelkefi A, Ben Othman T, Ladeb S, Torjman L, Ben Abdeladhim A. Rejection of the second allogeneic graft in a child with Fanconi anemia reversed by antilymphocyte globulin and donor lymphocyte infusion. Hematol J 2003;4:452-453.
25. Socie G, Devergie A, Girinski T, et al. Transplantation for Fanconi's anemia: Long-term follow-up of fifty patients transplanted from a sibling donor after a low-dose cyclophosphamide and thoraco-abdominal irradiation for conditioning. Br J Haematol 1998;103:249-255.
26. Guardiola P, Socie G, Pasquini R, et al. Allogeneic stem cell transplantation for Fanconi Anemia. Severe Aplastic Anaemia Working Party of the EBMT and EUFAR. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998;21:S24-S47.
27. Strathdee CA, Duncan AMV, Buchwald M. Evidence for at least four Fanconi anemia genes including FACC on chromosome 9. Nat Genet 1992;1:196-198.
28. Doney K, Leisering W, Storb R, et al. for the Seattle Bone Marrow Transplant Team. Primary treatment of acquired aplastic anemia: Outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med 1997;126:107-115.
29. Guardiola Ph, Socié G, Xiaxin Li, et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA identical sibling donors: Risk factors and influence on outcome. Blood 2004;103:73-77.
30. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34.